Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis

Chest

Volumn 146, Issue 1, 2014, Pages 41-50

  Doyle, Tracy J ^a   Dellaripa, Paul F ^a,b   Batra, Kerri ^a,f   Frits, Michelle L ^a,b   Iannaccone, Christine K ^a,b   Hatabu, Hiroto ^c,d   Nishino, Mizuki ^c,d   Weinblatt, Michael E ^a,b   Ascherman, Dana P ^f,g   Washko, George R ^a   Hunninghake, Gary M ^a,e   Choi, Augustine M K ^a   Shadick, Nancy A ^a,b   Rosas, Ivan O ^a,h,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GL 020 Gorman Building   (United States)

^c Center for Pulmonary Functional Imaging   (United States)

^d Center for Pulmonary Functional Imaging ^*  (United States)

^e CHANNING LABORATORY   (United States)

^f Department of Internal Medicine   (United States)

^g RHODE ISLAND HOSPITAL   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

ADULT; AGE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED VITAL CAPACITY; FUNCTIONAL DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKING; SYMPTOM; UNIVARIATE ANALYSIS;

AGED; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903836802     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1394     Document Type: Conference Paper

References (40)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the clas sifi cation of rheumatoid arthritis. Arthritis Rheum. 1988; 31 (3): 315-324.
2. Brown KK. Rheumatoid lung disease. Proc Am Th orac Soc. 2007; 4 (5): 443-448.
3. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis- interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011; 183 (3): 372-378.
4. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003; 62 (8): 722-727.
5. Bongartz T, Nannini C, Medina- Velasquez YF, et al. Inci dence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010; 62 (6): 1583-1591.
6. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012; 185 (11): 1147-1153.
7. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008; 168 (2): 159-166.
8. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fi brosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002; 61 (6): 517-521.
9. Shadick NA, Heller JE, Weinblatt ME, et al. Opposing eff ects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. Ann Rheum Dis. 2007; 66 (11): 1497-1502.
10. Iannaccone CK, Lee YC, Cui J, et al. Using genetic and clinical data to understand response to disease-modifying antirheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford). 2011; 50(1): 40-46.
11. Washko GR, Lynch DA, Matsuoka S, et al. Identifi cation of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol. 2010; 17 (1): 48-53.
12. Washko GR, Hunninghake GM, Fernandez IE, et al; COPDGene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011; 364 (10): 897-906.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999; 159 (1): 179-187.
14. ATS Committee on Profi ciency Standards for Clinical Pulmo nary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166 (1): 111-117.
15. Doyle TJ, Washko GR, Fernandez IE, et al; COPDGene Investigators. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med. 2012; 185 (7): 756-762.
16. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and mortality related to restriction on spirometry: fi ndings from the First National Health and Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis. 2005; 9 (6): 613-621.
17. Lederer DJ, Enright PL, Kawut SM, et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med. 2009; 180 (5): 407-414.
18. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fi brosis. A m J Respir Crit Care Med. 2007; 176 (7): 698-705.
19. Diaz de Leon A, Cronkhite JT, Yilmaz C, et al. Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. Chest. 2011; 140 (3): 753-763.
20. Kashiwabara K. Characteristics and disease activity of early interstitial lung disease in subjects with true parenchymal abnormalities in the posterior subpleural aspect of the lung. Chest. 2006; 129 (2): 402-406.
21. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001; 56 (8): 622-627.
22. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritisassociated interstitial lung disease. Chest. 2005; 127 (6): 2019-2027.
23. Akira M, Sakatani M, Hara H. Th insection CT fi ndings in rheumatoid arthritis-associated lung disease: CT patterns and their courses. J Comput Assist Tomogr. 1999; 23 (6): 941-948.
24. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fi brosis: evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 (6): 788-824.
25. American Thoracic Society; European Respiratory Society International American Thoracic Society/European Respira tory Society International Multi disciplinary Consensus Classifi - cation of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165 (2): 277-304
26. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009; 136 (5): 1397-1405.
27. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated inter stitial lung disease. E ur Respir J. 2010; 35 (6): 1322-1328.
28. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fi brosis. A m J Respir Crit Care Med. 2011; 183 (4): 431-440.
29. Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fi brosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008; 177 (2): 190-194.
30. Vassallo R, Ryu JH. Tobacco smokerelated diffuse lung diseases. Semin Respir Crit Care Med. 2008; 29 (6): 643-650.
31. Patel RR, Ryu JH, Vassallo R. Cigarette smoking and diff use lung disease. Drugs. 2008; 68 (11): 1511-1527.
32. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fi brosis. A m J Respir Crit Care Med. 1997; 155 (1): 242-248.
33. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996; 39 (10): 1711-1719.
34. King TE Jr. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011; 364 (10): 968-970.
35. Sverzellati N, Guerci L, Randi G, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J. 2011; 38 (2): 392-400.
36. Flaherty KR, Hunninghake GG. Smoking: an injury with many lung manifestations. Am J Respir Crit Care Med. 2005; 172 (9): 1070-1071.
37. Malik S, Saravanan V, Kelly C. Interstitial lung disease in rheumatoid arthritis: an update on diagnosis and management. Int J Clin Rheumatol. 2012; 7 (3): 297-308.
38. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006; 54 (1): 38-46.
39. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol. 2011; 38 (6): 979-982.
40. Luukkainen R, Saltyshev M, Pakkasela R, Nordqvist E, Huhtala H, Hakala M. Relationship of rheumatoid factor to lung diff usion capacity in smoking and non-smoking patients with rheumatoid arthritis. Scand J Rheumatol. 1995; 24 (2): 119-120.